These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29369948)

  • 1. Prognostic Value of Volume-Based Metabolic Parameters Obtained by 18F-FDG-PET/CT in Patients With Locally Advanced Squamous Cell Cervical Carcinoma.
    Liang Y; Li X; Wan H; Fang Y; Zheng R; Zhang W; Liu Y; Chen C; Wu N
    J Comput Assist Tomogr; 2018; 42(3):429-434. PubMed ID: 29369948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma.
    Sun Y; Lu P; Yu L
    Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (
    Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
    Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography.
    Yoo J; Choi JY; Moon SH; Bae DS; Park SB; Choe YS; Lee KH; Kim BT
    Int J Gynecol Cancer; 2012 Sep; 22(7):1226-33. PubMed ID: 22810970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
    AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of the Sum of Metabolic Tumor Volume of Primary Tumor and Lymph Nodes Using 18F-FDG PET/CT in Patients With Cervical Cancer.
    Hong JH; Min KJ; Lee JK; So KA; Jung US; Kim S; Eo JS
    Medicine (Baltimore); 2016 Mar; 95(9):e2992. PubMed ID: 26945420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-tumoral metabolic heterogeneity in
    Liu J; Ren Q; Xiao H; Li S; Zheng L; Yang X; Feng L; Zhou Z; Wang H; Yang J; Wang W
    Cancer Imaging; 2024 Jun; 24(1):72. PubMed ID: 38863073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
    Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer.
    Chung HH; Kang SY; Ha S; Kim JW; Park NH; Song YS; Cheon GJ
    J Gynecol Oncol; 2016 Mar; 27(2):e15. PubMed ID: 26768781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer.
    Yilmaz B; Dağ S; Ergul N; Çermik TF
    Nucl Med Commun; 2019 Mar; 40(3):219-227. PubMed ID: 30585896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of metabolic parameters determined by preoperative ¹⁸F-FDG PET/CT in patients with uterine carcinosarcoma.
    Lee HJ; Lee JJ; Park JY; Kim JH; Kim YM; Kim YT; Nam JH
    J Gynecol Oncol; 2017 Jul; 28(4):e43. PubMed ID: 28541634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of
    Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer.
    Hong JH; Jung US; Min KJ; Lee JK; Kim S; Eo JS
    Nucl Med Commun; 2016 Aug; 37(8):843-8. PubMed ID: 27058362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
    Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
    Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
    Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
    Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of 18F-FDG PET/CT metabolic, clinical and pathological characteristics of primary squamous cell carcinoma of the cervix.
    Xu W; Yu S; Xin J; Guo Q
    J Investig Med; 2016 Dec; 64(8):1246-1251. PubMed ID: 27436350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.
    Lim R; Eaton A; Lee NY; Setton J; Ohri N; Rao S; Wong R; Fury M; Schöder H
    J Nucl Med; 2012 Oct; 53(10):1506-13. PubMed ID: 22895812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor and metastatic lymph nodes metabolic activity on
    Song J; Pang W; Yi H; Ji J; Ye X; Li L
    Abdom Radiol (NY); 2024 Mar; 49(3):975-984. PubMed ID: 38302763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
    Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
    Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.